See the factory by live video walkthrough
Book an on-site factory visit in GuangzhouAccurate and compliant sunscreen labeling is critical for US market approval, retail acceptance, and consumer safety. Buyers and sourcing managers need to ensure every package meets FDA’s OTC sunscreen monograph requirements and aligns with…
Accurate and compliant sunscreen labeling is critical for US market approval, retail acceptance, and consumer safety. Buyers and sourcing managers need to ensure every package meets FDA’s OTC sunscreen monograph requirements and aligns with brand positioning. This guide outlines the statements, formatting, and evidence you should verify before approving production artwork.
The FDA requires the Drug Facts panel to be in a specific format, with minimum type size, bold headings, and section order. Artwork should be reviewed against 21 CFR Part 201.
| Label Element | Regulatory Basis | Evidence Needed |
|---|---|---|
| SPF Statement | FDA OTC Monograph 21 CFR Part 352 | SPF test report, artwork proof |
| Broad Spectrum | UVA requirements per FDA guidance | UVA test result, claim substantiation |
| Drug Facts Panel | 21 CFR Part 201 formatting | Final artwork file |
| Warnings | Standard OTC sunscreen warnings | Proof copy of warnings section |
If you change the formula or active percentages, you must retest. Otherwise, existing data can be used with appropriate rights and documentation.
No. Warnings must be verbatim from the FDA sunscreen monograph.
Artwork review should be locked before stability testing completes, to avoid print delays and compliance failures.
Yes. Any claim must be truthful, not misleading, and supported by ingredient list and marketing substantiation.
Request a Quote to ensure your sunscreen project meets US labeling standards from day one.